Cargando…

Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review

Dasatinib is a potent and effective second‐generation oral tyrosine kinase inhibitor that is clinically indicated for the treatment of imatinib‐resistant or imatinib‐intolerant breakpoint cluster region‐Abelson (BCR‐ABL)‐positive chronic myeloid leukaemia (CML) or for Philadelphia chromosome‐positiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Chao‐Chin, Hsu, Jui‐Feng, Wu, Kuan‐Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103079/
https://www.ncbi.nlm.nih.gov/pubmed/33976882
http://dx.doi.org/10.1002/rcr2.753
_version_ 1783689243715960832
author Hsu, Chao‐Chin
Hsu, Jui‐Feng
Wu, Kuan‐Li
author_facet Hsu, Chao‐Chin
Hsu, Jui‐Feng
Wu, Kuan‐Li
author_sort Hsu, Chao‐Chin
collection PubMed
description Dasatinib is a potent and effective second‐generation oral tyrosine kinase inhibitor that is clinically indicated for the treatment of imatinib‐resistant or imatinib‐intolerant breakpoint cluster region‐Abelson (BCR‐ABL)‐positive chronic myeloid leukaemia (CML) or for Philadelphia chromosome‐positive acute lymphocytic leukaemia. The most common adverse events associated with dasatinib therapy are skin rash, gastrointestinal upset, pancytopenia, pulmonary hypertension, and fluid retention, including pleural effusion. However, chylothorax secondary to dasatinib administration has rarely been reported. Although the underlying mechanism leading to dasatinib‐induced chylothorax is uncertain, the preferred treatment options are usually supported with diuretics or systemic steroids. Moreover, the discontinuation of the drug is mandatory in refractory cases. Here, we present the case of a patient with dasatinib‐induced chylothorax, and review the previously reported cases in the literature.
format Online
Article
Text
id pubmed-8103079
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-81030792021-05-10 Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review Hsu, Chao‐Chin Hsu, Jui‐Feng Wu, Kuan‐Li Respirol Case Rep Case Reports Dasatinib is a potent and effective second‐generation oral tyrosine kinase inhibitor that is clinically indicated for the treatment of imatinib‐resistant or imatinib‐intolerant breakpoint cluster region‐Abelson (BCR‐ABL)‐positive chronic myeloid leukaemia (CML) or for Philadelphia chromosome‐positive acute lymphocytic leukaemia. The most common adverse events associated with dasatinib therapy are skin rash, gastrointestinal upset, pancytopenia, pulmonary hypertension, and fluid retention, including pleural effusion. However, chylothorax secondary to dasatinib administration has rarely been reported. Although the underlying mechanism leading to dasatinib‐induced chylothorax is uncertain, the preferred treatment options are usually supported with diuretics or systemic steroids. Moreover, the discontinuation of the drug is mandatory in refractory cases. Here, we present the case of a patient with dasatinib‐induced chylothorax, and review the previously reported cases in the literature. John Wiley & Sons, Ltd 2021-05-07 /pmc/articles/PMC8103079/ /pubmed/33976882 http://dx.doi.org/10.1002/rcr2.753 Text en © 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Hsu, Chao‐Chin
Hsu, Jui‐Feng
Wu, Kuan‐Li
Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review
title Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review
title_full Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review
title_fullStr Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review
title_full_unstemmed Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review
title_short Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review
title_sort dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103079/
https://www.ncbi.nlm.nih.gov/pubmed/33976882
http://dx.doi.org/10.1002/rcr2.753
work_keys_str_mv AT hsuchaochin dasatinibinducedchylothoraxinapatientwithchronicmyeloidleukaemiaacasereportandliteraturereview
AT hsujuifeng dasatinibinducedchylothoraxinapatientwithchronicmyeloidleukaemiaacasereportandliteraturereview
AT wukuanli dasatinibinducedchylothoraxinapatientwithchronicmyeloidleukaemiaacasereportandliteraturereview